Xolair is a brand-name prescription medication known as a biologic. Its active ingredient is omalizumab. Generic versions of biologic drugs are called biosimilars. Due to complex manufacturing ...
Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved Omlyclo ® ...
On September 26, Amneal Pharmaceuticals, Inc. announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ADL-018, a proposed biosimilar to ...
Omalizumab or dupilumab suggested for adults with moderate-to-severe allergic asthma, history of exacerbations requiring oral corticosteroids ...
Kashiv Biosciences has submitted its Biologics License Applications (BLA) for ADL-018 as a biosimilar to reference product XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA) The ...
A year after the FDA blessed Roche and Novartis’ Xolair (omalizumab) as the first medicine to reduce allergic reactions that can occur from accidental exposure to certain foods, the companies have ...
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC today announced the completion of patient enrollment for its Phase III clinical trial of ADL018, a biosimilar candidate to XOLAIR®. This ...
PISCATAWAY, N.J.--(BUSINESS WIRE)-- Kashiv BioSciences, LLC, a fully-integrated biopharmaceutical company, announced that they have submitted a Biologics License Application (BLA) to the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results